Orthocell (ASX:OCC) signed eight additional US distributors for its nerve repair product Remplir, lifting its total to 12, according to a Friday filing with the Australian bourse.
The company is preparing for the first product use in the US market while also planning EU and UK regulatory filings within the next year, the filing said.